{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:25:13Z","timestamp":1777670713855,"version":"3.51.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vellore Institute of Technology, Vellore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML) has a survival rate of only 30%, predominantly affecting the bone marrow. AML is characterized by failure of bone marrow function to produce healthy blood cells resulting in significant clinical symptoms such as anemia, shortness of breath, and paleness of skin. This study focuses on elucidating the role of Histone Deacetylase 1 (HDAC1), a critical epigenetic regulator whose dysregulation has been recognized to contribute for AML prognosis. Although vorinostat is a well-established HDAC1 inhibitor, its resistance in cancer cells has necessitated the investigation of anti-leukemic phytochemicals as potential alternative therapeutic agents. A set of 800 unique anti-leukemic phytochemical compounds from 22 Indian plants were screened for pharmacokinetic properties revealed 33 compounds to have inhibitory effects. Further, toxicity screening revealed six compounds hispidulin, kumatakenin, phenyl glycoside, kaempferol, pelargonidin and rohitukine as potential lead candidates. Molecular docking studies indicated hispidulin with a notable binding affinity of -7.8\u00a0kcal\/mol whereas vorinostat had \u2212\u20096.51\u00a0kcal\/mol against HDAC1. Molecular dynamics simulations demonstrated a strong binding affinity of hispidulin to HDAC1, as indicated by an average root mean square deviation (RMSD) of 0.784\u00a0nm, an interaction energy (IE) of -208.42\u00a0kJ\/mol, and a total binding free energy of -28.32\u2009\u00b1\u20093.23\u00a0kcal\/mol. In comparison, vorinostat exhibited a higher RMSD of 0.868\u00a0nm, a slightly lower IE of -202.04\u00a0kJ\/mol, and a total binding free energy of -28.39\u2009\u00b1\u20094.81\u00a0kcal\/mol. These findings suggest that hispidulin exhibits superior binding stability and interaction strength with HDAC1 relative to vorinostat. Thus, hispidulin may serve as a promising lead compound for HDAC1 modulation, potentially enhancing therapeutic efficacy in the treatment of acute myeloid leukemia (AML).<\/jats:p>","DOI":"10.1007\/s12672-025-03182-y","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:17:44Z","timestamp":1753204664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hispidulin: a potential alternative to vorinostat against HDAC1 for acute myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9746-2204","authenticated-orcid":false,"given":"Sathyanarayan","family":"Balaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-6121","authenticated-orcid":false,"given":"Suvitha","family":"Anbarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-329X","authenticated-orcid":false,"given":"Sudha","family":"Ramaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-7488","authenticated-orcid":false,"given":"Anand","family":"Anbarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"3182_CR1","doi-asserted-by":"crossref","unstructured":"Kaspers GJL, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia vol. 19 2025\u20132029 (2005).","DOI":"10.1038\/sj.leu.2403958"},{"key":"3182_CR2","unstructured":"Howlader N et al. Seer is an authoritative source for cancer statistics in the united states. Vol. 2017. Bethesda, MD: National Cancer Institute, 2016. 2025 (2025). https:\/\/seer.cancer.gov\/statistics\/"},{"key":"3182_CR3","unstructured":"Acute Myeloid Leukemia Treatment (PDQ\u00ae): Health Professional Version. in. (2002)."},{"key":"3182_CR4","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1242\/dev.083147","volume":"140","author":"M Jagannathan-Bogdan","year":"2013","unstructured":"Jagannathan-Bogdan M, Zon LI. Hematopoiesis Development. 2013;140:2463\u20137.","journal-title":"Hematopoiesis Development"},{"key":"3182_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"3182_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/stem.3263","volume":"38","author":"T Matsukawa","year":"2020","unstructured":"Matsukawa T, Aplan PD. Clinical and molecular consequences of fusion genes in myeloid malignancies. Stem Cells. 2020;38:1366\u201374.","journal-title":"Stem Cells"},{"key":"3182_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5.","journal-title":"Mol Cancer"},{"key":"3182_CR8","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1101\/gad.284109.116","volume":"30","author":"D Hu","year":"2016","unstructured":"Hu D, Shilatifard A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev. 2016;30:2021\u201341.","journal-title":"Genes Dev"},{"key":"3182_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","volume":"9","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511\u201320.","journal-title":"Epigenetics"},{"key":"3182_CR10","doi-asserted-by":"crossref","unstructured":"Goettig P, Chen X, Harris JM. Correlation of experimental and calculated Inhibition constants of protease inhibitor complexes. Int J Mol Sci 25, 7 (2024).","DOI":"10.3390\/ijms25042429"},{"key":"3182_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"AJM de Ruijter","year":"2003","unstructured":"de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737\u201349.","journal-title":"Biochem J"},{"key":"3182_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1042\/BST20130010","volume":"41","author":"RDW Kelly","year":"2013","unstructured":"Kelly RDW, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans. 2013;41:741\u20139.","journal-title":"Biochem Soc Trans"},{"key":"3182_CR13","doi-asserted-by":"publisher","first-page":"zyae022","DOI":"10.1093\/intbio\/zyae022","volume":"16","author":"S Balaji","year":"2024","unstructured":"Balaji S, Anbarasu S, Ramaiah S, Anbarasu A. Targeting IKZF1 via HDAC1: combating acute myeloid leukemia. Integr Biol. 2024;16:zyae022.","journal-title":"Integr Biol"},{"key":"3182_CR14","doi-asserted-by":"crossref","unstructured":"Habibian JS, Ferguson BS. Chapter 13 - Histone modification as a potential preventative and therapeutic approach for cardiovascular disease. in Translational Epigenetics (eds. Castelo-Branco, P. & Jeronimo, C. B. T.-H. M. in T.) vol. 20 337\u2013359Academic Press, (2020).","DOI":"10.1016\/B978-0-12-816422-8.00014-3"},{"key":"3182_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gde.2019.04.013","volume":"55","author":"D Nicetto","year":"2019","unstructured":"Nicetto D, Zaret KS. Role of H3K9me3 heterochromatin in cell identity establishment and maintenance. Curr Opin Genet Dev. 2019;55:1\u201310.","journal-title":"Curr Opin Genet Dev"},{"key":"3182_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4161\/epi.21615","volume":"7","author":"YS Bogliotti","year":"2012","unstructured":"Bogliotti YS, Ross PJ. Mechanisms of histone H3 lysine 27 trimethylation remodeling during early mammalian development. Epigenetics. 2012;7:976\u201381.","journal-title":"Epigenetics"},{"key":"3182_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","volume":"51","author":"CJ Millard","year":"2013","unstructured":"Millard CJ, et al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell. 2013;51:57\u201367.","journal-title":"Mol Cell"},{"key":"3182_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/38664","volume":"389","author":"M Grunstein","year":"1997","unstructured":"Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349\u201352.","journal-title":"Nature"},{"key":"3182_CR19","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","volume":"5","author":"A Munshi","year":"2006","unstructured":"Munshi A, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5:1967\u201374.","journal-title":"Mol Cancer Ther"},{"key":"3182_CR20","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/1535-7163.MCT-07-0251","volume":"6","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic M, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther. 2007;6:2525\u201334.","journal-title":"Mol Cancer Ther"},{"key":"3182_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.20372","volume":"112","author":"A Villar-Garea","year":"2004","unstructured":"Villar-Garea A, Esteller M. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int J cancer. 2004;112:171\u20138.","journal-title":"Int J cancer"},{"key":"3182_CR22","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769\u201392.","journal-title":"Cancers (Basel)"},{"key":"3182_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2024-009099","volume":"12","author":"M Zhu","year":"2024","unstructured":"Zhu M, et al. Cantharidin overcomes IL-2R\u03b1 signaling-mediated Vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species. J Immunother Cancer. 2024;12:1\u201315.","journal-title":"J Immunother Cancer"},{"key":"3182_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1074\/jbc.M113.532978","volume":"289","author":"RC Bruntz","year":"2014","unstructured":"Bruntz RC, Taylor HE, Lindsley CW, Brown HA. Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem. 2014;289:600\u201316.","journal-title":"J Biol Chem"},{"key":"3182_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/jcp.29882","volume":"236","author":"DW Kang","year":"2021","unstructured":"Kang DW, et al. Phospholipase D1 is upregulated by Vorinostat and confers resistance to Vorinostat in glioblastoma. J Cell Physiol. 2021;236:549\u201360.","journal-title":"J Cell Physiol"},{"key":"3182_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CAD.0b013e3283262a32","volume":"20","author":"KJ Dedes","year":"2009","unstructured":"Dedes KJ, et al. Acquired Vorinostat resistance shows partial cross-resistance to \u2018second-generation\u2019 HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs. 2009;20:321\u201333.","journal-title":"Anticancer Drugs"},{"key":"3182_CR27","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon VM. Cancer biology: mechanism of antitumour action of Vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006;95:S2\u20136.","journal-title":"Br J Cancer"},{"key":"3182_CR28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16:991\u20131001.","journal-title":"Mol Cancer Ther"},{"key":"3182_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu X, Gong Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomark Res. 2019;7:22.","journal-title":"Biomark Res"},{"key":"3182_CR30","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH. Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198\u2013208.","journal-title":"Blood"},{"key":"3182_CR31","unstructured":"National cancer institute, USA, Drugs approved for leukemia drugs approved for acute lymphoblastic leukemia (ALL) drug combinations used in acute lymphoblastic leukemia drugs approved for acute myeloid leukemia (AML). 1\u20134 (2016). https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/leukemia"},{"key":"3182_CR32","doi-asserted-by":"crossref","unstructured":"Totiger TM et al. Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines 11, (2023).","DOI":"10.3390\/biomedicines11020641"},{"key":"3182_CR33","doi-asserted-by":"crossref","unstructured":"Maher T, et al. Medicinal plants with anti-leukemic effects: A review. Molecules 26, 2\u201319 (2021).","DOI":"10.3390\/molecules26092741"},{"key":"3182_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/01635581.2021.1924209","volume":"74","author":"O Izuegbuna","year":"2022","unstructured":"Izuegbuna O. Leukemia chemoprevention and therapeutic potentials: selected medicinal plants with Anti-Leukemic activities. Nutr Cancer. 2022;74:437\u201349.","journal-title":"Nutr Cancer"},{"key":"3182_CR35","doi-asserted-by":"publisher","first-page":"8827","DOI":"10.1021\/acsomega.3c00156","volume":"8","author":"RP Vivek-Ananth","year":"2023","unstructured":"Vivek-Ananth RP, Mohanraj K, Sahoo AK, Samal A. IMPPAT 2.0: an enhanced and expanded phytochemical atlas of Indian medicinal plants. ACS Omega. 2023;8:8827\u201345.","journal-title":"ACS Omega"},{"key":"3182_CR36","doi-asserted-by":"publisher","first-page":"e70780","DOI":"10.7554\/eLife.70780","volume":"11","author":"A Rutz","year":"2022","unstructured":"Rutz A, et al. The LOTUS initiative for open knowledge management in natural products research. Elife. 2022;11:e70780.","journal-title":"Elife"},{"key":"3182_CR37","unstructured":"Maha HL, Fidrianny I, Satrialdi, Suciati T. An updated review of Typhonium flagelliforme: phytochemical compound, Pharmacological activities and the use of vitexin and isovitexin as flavonoid compound in cosmetics development. Pharmacia 70, 673\u201380 (2023)."},{"key":"3182_CR38","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.ccmp.2021.100006","volume":"1","author":"EA Ugbogu","year":"2021","unstructured":"Ugbogu EA, et al. The phytochemistry, ethnobotanical, and Pharmacological potentials of the medicinal Plant-Vernonia amygdalina L. (bitter Leaf). Clin Complement Med Pharmacol. 2021;1:100006.","journal-title":"Clin Complement Med Pharmacol"},{"key":"3182_CR39","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51:D1373\u201380.","journal-title":"Nucleic Acids Res"},{"key":"3182_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, et al. The protein data bank. Nucleic Acids Res. 2000;28:235\u201342.","journal-title":"Nucleic Acids Res"},{"key":"3182_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V, SwissADME. A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:1\u201313.","journal-title":"Sci Rep"},{"key":"3182_CR42","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46:W257\u201363.","journal-title":"Nucleic Acids Res"},{"key":"3182_CR43","doi-asserted-by":"publisher","first-page":"11262","DOI":"10.1038\/ncomms11262","volume":"7","author":"PJ Watson","year":"2016","unstructured":"Watson PJ, et al. Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat Commun. 2016;7:11262.","journal-title":"Nat Commun"},{"key":"3182_CR44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605\u201312.","journal-title":"J Comput Chem"},{"key":"3182_CR45","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/elps.1150181505","volume":"18","author":"N Guex","year":"1997","unstructured":"Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18:2714\u201323.","journal-title":"Electrophoresis"},{"key":"3182_CR46","doi-asserted-by":"crossref","unstructured":"Elkhalifa AEO et al. Structure-Based Multi-Targeted Molecular Docking and Dynamic Simulation of Soybean-Derived Isoflavone Genistin as a Potential Breast Cancer Signaling Proteins Inhibitor. Life 13, (2023).","DOI":"10.3390\/life13081739"},{"key":"3182_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle NM, et al. Open babel: an open chemical toolbox. J Cheminform. 2011;3:33.","journal-title":"J Cheminform"},{"key":"3182_CR48","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, et al. AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"3182_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12551-016-0247-1","volume":"9","author":"NS Pagadala","year":"2017","unstructured":"Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a review. Biophys Rev. 2017;9:91\u2013102.","journal-title":"Biophys Rev"},{"key":"3182_CR50","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","volume":"19","author":"Morris","year":"1998","unstructured":"Morris, et al. Automated Docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639\u201362.","journal-title":"J Comput Chem"},{"key":"3182_CR51","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski RA, Swindells MB, LigPlot+. Multiple Ligand\u2013Protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778\u201386.","journal-title":"J Chem Inf Model"},{"key":"3182_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"GROMACS","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, et al. High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132. 2015;GROMACS:19\u201325.","journal-title":"SoftwareX 1\u20132"},{"key":"3182_CR53","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang J, MacKerell ADJ. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013;34:2135\u201345.","journal-title":"J Comput Chem"},{"key":"3182_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell MD, et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4:17.","journal-title":"J Cheminform"},{"key":"3182_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jcc.21600","volume":"32","author":"A Allouche","year":"2012","unstructured":"Allouche A. Software news and updates Gabedit \u2014 A graphical user interface for computational chemistry softwares. J Comput Chem. 2012;32:174\u201382.","journal-title":"J Comput Chem"},{"key":"3182_CR56","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR 3rd Miller","year":"2012","unstructured":"Miller BR, 3rd, et al. MMPBSA.py: an efficient program for End-State free energy calculations. J Chem Theory Comput. 2012;8:3314\u201321.","journal-title":"J Chem Theory Comput"},{"key":"3182_CR57","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E, gmx_MMPBSA. A new tool to perform End-State free energy calculations with GROMACS. J Chem Theory Comput. 2021;17:6281\u201391.","journal-title":"J Chem Theory Comput"},{"key":"3182_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/prot.340040104","volume":"4","author":"MK Gilson","year":"1988","unstructured":"Gilson MK, Honig B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins. 1988;4:7\u201318.","journal-title":"Proteins"},{"key":"3182_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1021\/ct050097l","volume":"2","author":"RC Rizzo","year":"2006","unstructured":"Rizzo RC, Aynechi T, Case DA, Kuntz ID. Estimation of absolute free energies of hydration using continuum methods: accuracy of partial charge models and optimization of nonpolar contributions. J Chem Theory Comput. 2006;2:128\u201339.","journal-title":"J Chem Theory Comput"},{"key":"3182_CR60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/minf.201100135","volume":"31","author":"N Homeyer","year":"2012","unstructured":"Homeyer N, Gohlke H. Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Mol Inf. 2012;31:114\u201322.","journal-title":"Mol Inf"},{"key":"3182_CR61","doi-asserted-by":"publisher","first-page":"741746","DOI":"10.3389\/fonc.2021.741746","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Gao X, Yu L. Roles of histone deacetylases in acute myeloid leukemia with fusion proteins. Front Oncol. 2021;11:741746.","journal-title":"Front Oncol"},{"key":"3182_CR62","first-page":"2923","volume":"20","author":"C Xia","year":"2020","unstructured":"Xia C, Tao Y, Li M, Che T, Qu J. Protein acetylation and deacetylation: an important regulatory modification in gene transcription (Review). Exp Ther Med. 2020;20:2923\u201340.","journal-title":"Exp Ther Med"},{"key":"3182_CR63","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fphar.2020.00832","volume":"11","author":"B Tinoush","year":"2020","unstructured":"Tinoush B, Shirdel I, Wink M. Phytochemicals: potential lead molecules for MDR reversal. Front Pharmacol. 2020;11:832.","journal-title":"Front Pharmacol"},{"key":"3182_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1359-6446(01)02100-6","volume":"7","author":"HE Selick","year":"2002","unstructured":"Selick HE, Beresford AP, Tarbit MH. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today. 2002;7:109\u201316.","journal-title":"Drug Discov Today"},{"key":"3182_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jddst.2016.06.014","volume":"35","author":"G Lamberti","year":"2016","unstructured":"Lamberti G, et al. Gastrointestinal behavior and ADME phenomena: II. In Silico simulation. J Drug Deliv Sci Technol. 2016;35:165\u201371.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3182_CR66","doi-asserted-by":"publisher","unstructured":"Daina A, Zoete VA, BOILED-Egg To. Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem 1117\u20131121 (2016) https:\/\/doi.org\/10.1002\/cmdc.201600182","DOI":"10.1002\/cmdc.201600182"},{"key":"3182_CR67","doi-asserted-by":"crossref","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","DOI":"10.1016\/S0169-409X(00)00129-0"},{"key":"3182_CR68","doi-asserted-by":"publisher","unstructured":"Polinsky A. Chapter 12 - Lead-Likeness and Drug-Likeness. in (ed. Wermuth, C. G. B. T.-T. P. of M. C. (Third E.) 244\u2013254Academic Press, (2008). https:\/\/doi.org\/10.1016\/B978-0-12-374194-3.00012-3","DOI":"10.1016\/B978-0-12-374194-3.00012-3"},{"key":"3182_CR69","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/js9804011","volume":"88","author":"DE Clark","year":"1999","unstructured":"Clark DE. Rapid calculation of Polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci. 1999;88:807\u201314.","journal-title":"J Pharm Sci"},{"key":"3182_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1758-2946-1-8","volume":"1","author":"P Ertl","year":"2009","unstructured":"Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 2009;1:8.","journal-title":"J Cheminform"},{"key":"3182_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/bta.2021.103765","volume":"102","author":"CJ Ononamadu","year":"2021","unstructured":"Ononamadu CJ, Ibrahim A. Molecular Docking and prediction of ADME\/drug-likeness properties of potentially active antidiabetic compounds isolated from aqueous-methanol extracts of Gymnema sylvestre and Combretum micranthum. Biotechnologia. 2021;102:85\u201399.","journal-title":"Biotechnologia"},{"key":"3182_CR72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/wcms.1240","volume":"6","author":"AB Raies","year":"2016","unstructured":"Raies AB, Bajic VB. In Silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016;6:147\u201372.","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"3182_CR73","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete JT, Gy\u0151rffy B. ROCplot.org: validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J Cancer. 2019;145:3140\u201351.","journal-title":"Int J Cancer"},{"key":"3182_CR74","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkt1031","volume":"42","author":"AP Bento","year":"2014","unstructured":"Bento AP, et al. The chembl bioactivity database: an update. Nucleic Acids Res. 2014;42:D1083\u201390.","journal-title":"Nucleic Acids Res"},{"key":"3182_CR75","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.fct.2017.05.041","volume":"107","author":"AK Schrey","year":"2017","unstructured":"Schrey AK, et al. Computational prediction of immune cell cytotoxicity. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2017;107:150\u201366.","journal-title":"Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc"},{"key":"3182_CR76","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/ci900161g","volume":"49","author":"K Hansen","year":"2009","unstructured":"Hansen K, et al. Benchmark data set for in Silico prediction of Ames mutagenicity. J Chem Inf Model. 2009;49:2077\u201381.","journal-title":"J Chem Inf Model"},{"key":"3182_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02763860802198895","volume":"27","author":"RB Fitzpatrick","year":"2008","unstructured":"Fitzpatrick RB. CPDB: carcinogenic potency database. Med Ref Serv Q. 2008;27:303\u201311.","journal-title":"Med Ref Serv Q"},{"key":"3182_CR78","doi-asserted-by":"crossref","unstructured":"Mitkov J, Kondeva-Burdina M, Zlatkov A. Synthesis and preliminary hepatotoxicity evaluation of new caffeine-8-(2-thio)-propanoic hydrazid-hydrazone derivatives. Pharmacia. (2019);66:99\u2013106.","DOI":"10.3897\/pharmacia.66.e37263"},{"key":"3182_CR79","doi-asserted-by":"crossref","unstructured":"Fareed MM et al. In Silico Drug Screening Analysis against the Overexpression of PGAM1 Gene in Different Cancer Treatments. Biomed Res. Int. 2021, (2021).","DOI":"10.1155\/2021\/5515692"},{"key":"3182_CR80","doi-asserted-by":"publisher","first-page":"132407","DOI":"10.1016\/j.molstruc.2022.132407","volume":"1255","author":"R Raveesha","year":"2022","unstructured":"Raveesha R, et al. Synthesis, in Silico ADME, toxicity prediction and molecular Docking studies of N-substituted [1,2,4]triazolo[4,3-a]pyrazine derivatives as potential anticonvulsant agents. J Mol Struct. 2022;1255:132407.","journal-title":"J Mol Struct"},{"key":"3182_CR81","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1039\/b617121b","volume":"37","author":"AI Anzellotti","year":"2008","unstructured":"Anzellotti AI, Farrell NP. Zinc metalloproteins as medicinal targets. Chem Soc Rev. 2008;37:1629\u201351.","journal-title":"Chem Soc Rev"},{"key":"3182_CR82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","volume":"59","author":"NJ Porter","year":"2019","unstructured":"Porter NJ, Christianson DW. Structure, mechanism, and Inhibition of the zinc-dependent histone deacetylases. Curr Opin Struct Biol. 2019;59:9\u201318.","journal-title":"Curr Opin Struct Biol"},{"key":"3182_CR83","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.embor.7401047","volume":"8","author":"A Vannini","year":"2007","unstructured":"Vannini A, et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep. 2007;8:879\u201384.","journal-title":"EMBO Rep"},{"key":"3182_CR84","doi-asserted-by":"publisher","first-page":"e76355","DOI":"10.1371\/journal.pone.0076355","volume":"8","author":"C Behrens","year":"2013","unstructured":"Behrens C, et al. Crystal structure of the human short coiled coil protein and insights into SCOC-FEZ1 complex formation. PLoS ONE. 2013;8:e76355.","journal-title":"PLoS ONE"},{"key":"3182_CR85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1134\/S0026893308040195","volume":"42","author":"MI Lobanov","year":"2008","unstructured":"Lobanov MI, Bogatyreva NS, Galzitskaia OV. [Radius of gyration is indicator of compactness of protein structure]. Mol Biol (Mosk). 2008;42:701\u20136.","journal-title":"Mol Biol (Mosk)"},{"key":"3182_CR86","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1080\/07391102.2020.1850356","volume":"40","author":"T Joshi","year":"2022","unstructured":"Joshi T, et al. Repurposing of FDA approved drugs against Salmonella enteric serovar Typhi by targeting dihydrofolate reductase: an in Silico study. J Biomol Struct Dyn. 2022;40:3731\u201344.","journal-title":"J Biomol Struct Dyn"},{"key":"3182_CR87","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1021\/acsomega.4c00929","volume":"9","author":"T Joshi","year":"2024","unstructured":"Joshi T, et al. Identifying novel therapeutics for the resistant mutant F533L in PBP3 of Pseudomonas aeruginosa using ML techniques. ACS Omega. 2024;9:28046\u201360.","journal-title":"ACS Omega"},{"key":"3182_CR88","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.sjbs.2023.103753","volume":"30","author":"ZK Bagewadi","year":"2023","unstructured":"Bagewadi ZK, et al. Molecular dynamics and simulation analysis against superoxide dismutase (SOD) target of Micrococcus luteus with secondary metabolites from Bacillus licheniformis recognized by genome mining approach. Saudi J Biol Sci. 2023;30:103753.","journal-title":"Saudi J Biol Sci"},{"key":"3182_CR89","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0009-2614(01)00859-4","volume":"345","author":"I Tavernelli","year":"2001","unstructured":"Tavernelli I, Di Iorio EE. The interplay between protein dynamics and frustration of non-bonded interactions as revealed by molecular dynamics simulations. Chem Phys Lett. 2001;345:287\u201394.","journal-title":"Chem Phys Lett"},{"key":"3182_CR90","doi-asserted-by":"publisher","first-page":"108390","DOI":"10.1016\/j.carres.2021.108390","volume":"507","author":"M Maszota-Zieleniak","year":"2021","unstructured":"Maszota-Zieleniak M, Zsila F, Samsonov SA. Computational insights into heparin-small molecule interactions: evaluation of the balance between stacking and non-stacking binding modes. Carbohydr Res. 2021;507:108390.","journal-title":"Carbohydr Res"},{"key":"3182_CR91","doi-asserted-by":"publisher","unstructured":"Maiti P, et al. Potent multi-target natural inhibitors against SARS-CoV-2 from medicinal plants of the himalaya: a discovery from hybrid machine learning, chemoinformatics, and simulation assisted screening. J Biomol Struct Dyn. 2023;1\u201314. https:\/\/doi.org\/10.1080\/07391102.2023.2257333.","DOI":"10.1080\/07391102.2023.2257333"},{"key":"3182_CR92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.sajb.2017.09.017","volume":"113","author":"AA Ajao","year":"2017","unstructured":"Ajao AA, Moteetee AN. South African journal of botany Tithonia diversifolia (Hemsl) A. Gray. (Asteraceae: Heliantheae), an invasive plant of signi fi cant ethnopharmacological importance: A review. South Afr J Bot. 2017;113:396\u2013403.","journal-title":"South Afr J Bot"},{"key":"3182_CR93","doi-asserted-by":"crossref","unstructured":"Thuy TT, et al. Sesquiterpenoids from Tithonia diversifolia (Hemsl.) A. Gray induce apoptosis and inhibit the cell cycle progression of acute myeloid leukemia cells. 78, 65\u201372 (2023).","DOI":"10.1515\/znc-2021-0154"},{"key":"3182_CR94","doi-asserted-by":"publisher","first-page":"118395","DOI":"10.1016\/j.lfs.2020.118395","volume":"259","author":"K Liu","year":"2020","unstructured":"Liu K, et al. Hispidulin: A promising flavonoid with diverse anti-cancer properties. Life Sci. 2020;259:118395.","journal-title":"Life Sci"},{"key":"3182_CR95","doi-asserted-by":"publisher","first-page":"124766","DOI":"10.1016\/j.ijpharm.2024.124766","volume":"666","author":"Z Sapiun","year":"2024","unstructured":"Sapiun Z, et al. Hispidulin-rich fraction of Clerodendrum fragrans wild. (Sesewanua) dissolving microneedle as antithrombosis candidate: A proof of concept study. Int J Pharm. 2024;666:124766.","journal-title":"Int J Pharm"},{"key":"3182_CR96","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1186\/s12885-024-12715-7","volume":"24","author":"S Fakhri","year":"2024","unstructured":"Fakhri S, et al. Phytochemicals regulate cancer metabolism through modulation of the AMPK\/PGC-1\u03b1 signaling pathway. BMC Cancer. 2024;24:1079.","journal-title":"BMC Cancer"},{"key":"3182_CR97","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.biopha.2018.04.014","volume":"103","author":"M Han","year":"2018","unstructured":"Han M, et al. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPAR\u03b3. Biomed Pharmacother. 2018;103:272\u201383.","journal-title":"Biomed Pharmacother"},{"key":"3182_CR98","first-page":"1115","volume":"8","author":"H Gao","year":"2016","unstructured":"Gao H, et al. Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer. Am J Transl Res. 2016;8:1115\u201332.","journal-title":"Am J Transl Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03182-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:47:40Z","timestamp":1757270860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03182-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3182"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03182-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1389"}}